Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Recent Articles
FDA Proposes Adding Drug Prices to Advertising
The U.S. Food and Drug Administration’s (FDA’s) proposal to require pharmaceutical companies to include drug prices in consumer advertising has led to more questions...
Insurers and Physicians Clash Over “Avoidable Visits”
Anthem, one of the largest health insurance companies in the U.S., is coming under fire for denying patients’ claims for emergency room visits for...
New Guidelines Encourage Exercise for All Cancer Patients
Standard care for patients with cancer should include exercise, according to a new position statement from the Clinical Oncology Society of Australia (COSA). The...
CRISPR Pioneers Launch New Gene-Editing Company
The pioneers of CRISPR technology have founded Beam Therapeutics, a new company that will explore base editing, a new, more precise form of gene...
FDA Expands Daratumumab’s Indication to Frontline Myeloma Treatment
The U.S. Food and Drug Administration (FDA) has approved daratumumab in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of patients with...
Current Issue
May 2018, Volume 4, Issue 6
This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.
